Sangamo Therapeutics (SGMO) Fundamental Analysis: Revenue, Earnings & Valuation

3.80 / 10

Netural

Fundamental analysis scores 3.8/10, indicating a weak picture. Cash‑to‑market and inventory turnover are strengths, but fixed‑asset turnover, revenue‑to‑market and a –49.6% YoY revenue decline are major concerns. Overall, the balance sheet offers limited upside.

Analysis Checks(6/10)

Revenue-MV

Value-3.90

Score1/3

Weight13.65%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value-49.60

Score1/3

Weight-6.47%

1M Return-3.06%

Inventory turnover ratio

Value47.95

Score3/3

Weight18.11%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight4.13%

1M Return1.69%

PB-ROE

Value0.61

Score0/3

Weight9.11%

1M Return3.23%

Income tax / Total profit (%)

Value0.02

Score2/3

Weight2.42%

1M Return1.04%

Fixed assets turnover ratio

Value0.79

Score1/3

Weight-2.53%

1M Return-1.24%

Cost of sales ratio (%)

Value70.31

Score3/3

Weight10.47%

1M Return4.32%

Asset-MV

Value-0.49

Score2/3

Weight35.01%

1M Return12.22%

Cash-MV

Value-0.09

Score2/3

Weight16.08%

1M Return5.94%

Is SGMO undervalued or overvalued?

SGMO scores 3.80/10 on fundamentals and holds a Fair valuation at present. Backed by its -2891.84% ROE, -310.81% net margin, -0.73 P/E ratio, -6.25 P/B ratio, and 10.20% earnings growth, these metrics solidify its Netural investment rating.